<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-13-08468</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0068768</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Cardiovascular</subject><subj-group><subject>Stroke</subject></subj-group></subj-group><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Pathology</subject><subj-group><subject>General pathology</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group><subject>Clinical laboratory sciences</subject></subj-group></subj-group><subj-group><subject>Epidemiology</subject><subj-group><subject>Biomarker epidemiology</subject></subj-group></subj-group><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular diseases</subject><subj-group><subject>Ischemic stroke</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Plasma Midregional Pro-Adrenomedullin Improves Prediction of Functional Outcome in Ischemic Stroke</article-title>
<alt-title alt-title-type="running-head">MR-proADM in Ischemic Stroke</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Seifert-Held</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Pekar</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gattringer</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Simmet</surname><given-names>Nicole E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Scharnagl</surname><given-names>Hubert</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bocksrucker</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lampl</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Storch</surname><given-names>Maria K.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
    <contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Stojakovic</surname><given-names>Tatjana</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="fn" rid="fn1">
        <sup>¶</sup>
    </xref></contrib>
    <contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fazekas</surname><given-names>Franz</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="fn" rid="fn1">
        <sup>¶</sup>
    </xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of Neurology, Medical University of Graz, Graz, Austria</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>University of Applied Sciences Wiener Neustadt, Wiener Neustadt, Austria</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria</addr-line></aff>
<aff id="aff4"><label>4</label><addr-line>Konventhospital Barmherzige Brueder Linz, Linz, Austria</addr-line></aff>
<aff id="aff5"><label>5</label><addr-line>Konventhospital Barmherzige Schwestern Linz, Linz, Austria</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Arumugam</surname><given-names>Thiruma V.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Queensland, Australia</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">thomas.seifert@medunigraz.at</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: TSH TP CL MKS TS FF. Performed the experiments: TSH TP CB TS. Analyzed the data: TSH TP HS MKS TS FF. Contributed reagents/materials/analysis tools: TSH TP TG NES HS CB TS. Wrote the paper: TSH TP MKS TS FF.</p></fn>
    <fn id="fn1" fn-type="other">
        <p>¶ These authors also contributed equally to this work.</p>
    </fn>
</author-notes>
<pub-date pub-type="collection"><year>2013</year></pub-date>
<pub-date pub-type="epub"><day>22</day><month>7</month><year>2013</year></pub-date>
<volume>8</volume>
<issue>7</issue>
<elocation-id>e68768</elocation-id>
<history>
<date date-type="received"><day>25</day><month>2</month><year>2013</year></date>
<date date-type="accepted"><day>2</day><month>6</month><year>2013</year></date>
</history>
<permissions>
<copyright-year>2013</copyright-year>
<copyright-holder>Seifert-Held et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title>Background</title>
<p>To evaluate if plasma levels of midregional pro-adrenomedullin (MR-proADM) improve prediction of functional outcome in ischemic stroke.</p>
</sec><sec>
<title>Methods</title>
<p>In 168 consecutive ischemic stroke patients, plasma levels of MR-proADM were measured within 24 hours from symptom onset. Functional outcome was assessed by the modified Rankin Scale (mRS) at 90 days following stroke. Logistic regression, receiver operating characteristics (ROC) curve analysis, net reclassification improvement (NRI), and Kaplan-Meier survival analysis were applied.</p>
</sec><sec>
<title>Results</title>
<p>Plasma MR-proADM levels were found significantly higher in patients with unfavourable (mRS 3–6) compared to favourable (mRS 0–2) outcomes. MR-proADM levels were entered into a predictive model including the patients' age, National Institutes of Health Stroke Scale (NIHSS), and the use of recanalization therapy. The area under the ROC curve did not increase significantly. However, category-free NRI of 0.577 (p&lt;0.001) indicated a significant improvement in reclassification of patients. Furthermore, MR-proADM levels significantly improved reclassification of patients in the prediction of outcome by the Stroke Prognostication using Age and NIHSS-100 (SPAN-100; NRI = 0.175; p = 0.04). Kaplan-Meier survival analysis showed a rising risk of death with increasing MR-proADM quintiles.</p>
</sec><sec>
<title>Conclusions</title>
<p>Plasma MR-proADM levels improve prediction of functional outcome in ischemic stroke when added to the patients' age, NIHSS on admission, and the use of recanalization therapy. Levels of MR-proADM in peripheral blood improve reclassification of patients when the SPAN-100 is used to predict the patients' functional outcome.</p>
</sec></abstract>
<funding-group><funding-statement>This study was supported by an in-house grant of the Medical University of Graz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="5"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Ischemic stroke is among the leading causes of death and disability and utilises a huge amount of health care expenses. Clinical criteria which predict worse functional outcome include increased age and higher National Institutes of Health Stroke Scale (NIHSS) on admission. <xref ref-type="bibr" rid="pone.0068768-Weimar1">[1]</xref> Early pharmacological recanalization improves outcome compared to placebo treatment. <xref ref-type="bibr" rid="pone.0068768-Frendl1">[2]</xref> A potential biomarker should provide predictive information in addition to established prognostic criteria. <xref ref-type="bibr" rid="pone.0068768-Whiteley1">[3]</xref> Several proteins in peripheral blood which are related to an acute stress response have recently been shown to improve outcome prediction in ischemic stroke. <xref ref-type="bibr" rid="pone.0068768-DeMarchis1">[4]</xref>–<xref ref-type="bibr" rid="pone.0068768-Doehner1">[7]</xref> As derived from observations in patients with myocardial infarction and congestive heart failure (CHF), plasma midregional pro-adrenomedullin (MR-proADM) is an independent predictor of death. <xref ref-type="bibr" rid="pone.0068768-Khan1">[8]</xref>, <xref ref-type="bibr" rid="pone.0068768-vonHaehling1">[9]</xref> We hypothesized that MR-proADM would also reflect the acute stress response in ischemic stroke and could therefore be used to predict functional outcome. MR-proADM is a non-functional precursor of adrenomedullin. <xref ref-type="bibr" rid="pone.0068768-Gumusel1">[10]</xref> This protein has been originally isolated from pheochromocytoma and is found in different organs and tissues including vascular smooth muscle cells and endothelium. <xref ref-type="bibr" rid="pone.0068768-Sugo1">[11]</xref>–<xref ref-type="bibr" rid="pone.0068768-Kitamura1">[13]</xref> Thereby, it exerts vasodilating, vasoprotective and angiogenic effects. <xref ref-type="bibr" rid="pone.0068768-Kato1">[14]</xref> Adrenomedullin is difficult to measure in peripheral blood because of complex formation and rapid clearance from the circulation. <xref ref-type="bibr" rid="pone.0068768-Pio1">[15]</xref>, <xref ref-type="bibr" rid="pone.0068768-Meeran1">[16]</xref> The more stable MR-proADM is secreted in equimolar amounts to adrenomedullin and can be reliably detected in human plasma. <xref ref-type="bibr" rid="pone.0068768-Struck1">[17]</xref>, <xref ref-type="bibr" rid="pone.0068768-Morgenthaler1">[18]</xref>.</p>
</sec><sec id="s2" sec-type="methods">
<title>Methods</title>
<sec id="s2a">
<title>Ethics statement</title>
<p>The study was approved by institutional review boards of the Medical University of Graz and Konventhospital Barmherzige Brueder Linz. Written informed consent was obtained from all participants. For patients with impaired consciousness or aphasia, written informed consent was obtained when these patients regained the ability to communicate.</p>
</sec><sec id="s2b">
<title>Patients</title>
<p>Consecutive patients admitted between September 2010 and June 2012 to stroke units of the Departments of Neurology, Medical University of Graz and Konventhospital Barmherzige Brueder Linz, were considered for participation in this study. Patients with acute hemispheric, cerebellar or brainstem ischemia according to clinical examination and brain imaging (computerized tomography or magnetic resonance imaging) were eligible when they had a NIHSS <xref ref-type="bibr" rid="pone.0068768-Brott1">[19]</xref> of more than 3 on admission and a modified Rankin Scale (mRS) <xref ref-type="bibr" rid="pone.0068768-vanSwieten1">[20]</xref> of 0 or 1 before symptom onset. Blood sampling for this study had to be performed within 24 h from symptom onset and before initiation of recanalization therapy (intravenous or intraarterial thrombolysis, endovascular thrombectomy). Subjects with minor stroke (NIHSS &lt;3), transitory ischemic attack (TIA) or evidence for infectious disease on admission were not included. Patients were not eligible when they had major surgery or transfusion of blood components within one month prior to their stroke. Further exclusion criteria were applied as follows: acute renal failure, acute myocardial infarction, chronic hemodialysis, CHF New York Heart Association (NYHA) classes III and IV, active malignancy, immunosuppressive therapy.</p>
</sec><sec id="s2c">
<title>Clinical variables and laboratory procedure</title>
<p>The NIHSS was obtained on admission by board certified neurologists. The mRS at day 90 following stroke was obtained during a routine follow-up visit or by telephone interviews with patients or their caregivers. <xref ref-type="bibr" rid="pone.0068768-Janssen1">[21]</xref> The Stroke Prognostication using Age and NIHSS (SPAN) was obtained by combining the patients' age in years and NIHSS on admission. <xref ref-type="bibr" rid="pone.0068768-Saposnik1">[22]</xref> Individuals with SPAN &gt;100 were considered SPAN-100 positive, and those with SPAN &lt;100 were SPAN-100 negative. In a recent analysis, SPAN-100 positivity was associated with a significant lower odds of a composite favourable outcome (mRS &lt;1, NIHSS &lt;1, Barthel index &gt;95, Glasgow Outcome Scale score 1) at three months following stroke after adjusting for thrombolytic treatment. <xref ref-type="bibr" rid="pone.0068768-Saposnik1">[22]</xref> Stroke was classified according to the Oxfordshire Community Stroke Project (OCSP) <xref ref-type="bibr" rid="pone.0068768-Bamford1">[23]</xref> and the Causative Classification of Stroke System (CCS). <xref ref-type="bibr" rid="pone.0068768-Ay1">[24]</xref> Cerebrovascular risk factors were identified as defined by preadmission history or the need for medication at discharge: hypertension, hypercholesterolaemia, and diabetes mellitus. Atrial fibrillation was diagnosed either by history, an electrocardiogram (ECG) on admission, or Holter-ECG during the hospital stay. Clinical care was performed according to guidelines of the European Stroke Organisation. Blood was drawn by venipuncture and collected into EDTA-coated tubes. Plasma was stored at −70°C for further analysis. Plasma MR-proADM was measured by a commercial chemoluminescence assay on a KRYPTOR® system (Thermo Scientific B<sup>.</sup>R<sup>.</sup>A<sup>.</sup>H<sup>.</sup>M<sup>.</sup>S, Hennigsdorf, Germany). <xref ref-type="bibr" rid="pone.0068768-Morgenthaler1">[18]</xref> Measurements were performed blinded to all clinical data.</p>
</sec><sec id="s2d">
<title>Statistical analysis</title>
<p>Student's t-test, Mann-Whitney's U-test, the Chi-square test or Fisher's exact test, and Spearman's rank order correlation were applied for two-group comparisons. Backwards elimination logistic regression was performed to generate predictive models for functional outcome at day 90 following stroke. Patients were dichotomized into favourable (mRS 0–2) and unfavourable (mRS 3–6) outcomes. From a previous small exploratory study, a sample size of 146 patients was derived to obtain significantly different MR-proADM levels between these patient groups with α = 0.05 and 80% power. To evaluate the added predictive ability of MR-proADM, discrimination of models was assessed by comparing areas under receiver operating characteristics (ROC) curves (AUC) <xref ref-type="bibr" rid="pone.0068768-DeLong1">[25]</xref> and category-free net reclassification improvement (NRI) <xref ref-type="bibr" rid="pone.0068768-Pencina1">[26]</xref> was applied. NRI offers incremental information over the comparison of AUCs of ROC curves. <xref ref-type="bibr" rid="pone.0068768-Pencina2">[27]</xref> Category-free NRI is not influenced by correct scaling of the model and offers the widest and most standardized application in quantification of improvement. <xref ref-type="bibr" rid="pone.0068768-Pencina1">[26]</xref> Based on outcome prediction by the use of the SPAN-100, categorial NRI was obtained by reclassification of patients according to their plasma MR-proADM quintiles. SPAN-100 negative patients in the upper three quintiles were reclassified upwards. SPAN-100 positive patients in the lower two quintiles were reclassified downwards. Z-statistics were calculated as described previously, <xref ref-type="bibr" rid="pone.0068768-Pencina2">[27]</xref> and p-value was obtained by GraphPad software. Comparison of ROC curves and Kaplan-Meier analysis were done with MedCalc 11.6.1. and sample size calculation with G*Power 3.1. <xref ref-type="bibr" rid="pone.0068768-Faul1">[28]</xref> Other analyses were performed by IBM SPSS Statistics version 20 and R version 2.15.1.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<p>168 patients were included in the study, 85 men and 83 women at a mean age of 72.9 years (median 74; range 18–97), all of them Caucasians. Blood samples were collected within 12 hours in 138 (82.1%) and between 12 and 24 hours in 30 (17.9%) patients. 90 (53.6%) patients received revascularization therapy. Patients had a median NIHSS of 9 (range 4–25) on admission. No significant differences in the NIHSS were found between patients who received recanalization therapy and them who didn't. No significant differences in the NIHSS were found between men and women, and whether patients had blood sampling within 12 hours from symptom onset or afterwards. Stroke was classified according to the OCSP as follows: 19.6% total anterior circulation syndrome (TACS), 60.2% partial anterior circulation syndrome (PACS), 13.1% posterior circulation syndrome (POCS) and 7.1% lacunar syndrome (LACS). Causes of stroke according to the CCS were found as follows: 33.9% supra-aortic atherosclerosis, 43.5% cardio-aortic embolism, 7.1% small artery occlusion, 15.5% uncommon/undetermined causes. Cerebrovascular risk factors were found as follows: hypertension in 130 (77.4%), hypercholesterolemia in 86 (51.2%), diabetes mellitus in 40 (23.8%), and atrial fibrillation in 68 (40.5%) patients. Correlations of plasma MR-proADM were found with the patients' age (r<sub>S</sub> = 0.34; p&lt;0.001), NIHSS on admission (r<sub>S</sub> = 0.18; p = 0.023) and mRS at day 90 (r<sub>S</sub> = 0.33; p&lt;0.001). MR-proADM levels did not significantly differ between men and women, between patients with diabetes mellitus or without, and between patients with hypercholesterolemia or without. Higher median MR-proADM levels were found in patients with hypertension (0.77 vs. 0.64 nmol/l; p = 0.005), atrial fibrillation (0.85 vs. 0.70 nmol/l; p&lt;0.001) and coronary heart disease (0.82 vs. 0.74 nmol/l; p = 0.041).</p>
<p>Patients had a median mRS of 3 at day 90. Patients with unfavourable outcome were significantly older, had a higher median NIHSS, a higher proportion of TACS and a higher prevalence of atrial fibrillation and cardio-aortic embolism as the cause of stroke (<xref ref-type="table" rid="pone-0068768-t001">table 1</xref>). Plasma MR-proADM was found significantly higher in patients with unfavourable compared to favourable outcomes (median 0.84 vs. 0.68 nmol/l; p&lt;0.001; <xref ref-type="fig" rid="pone-0068768-g001">figure 1</xref>). Predictive models were generated to assess the value of adding MR-proADM plasma levels to the patients' age, NIHSS on admission, and the use of recanalization therapy (<xref ref-type="table" rid="pone-0068768-t002">table 2</xref>). The AUC of generated ROC curves did not increase significantly when plasma MR-proADM levels were added (0.803 and 0.819 for models 1 and 2, respectively; p = 0.204). Category-free NRI of 0.577 (p&lt;0.001) indicated a significant improvement in reclassification of patients by adding MR-proADM levels to predict functional outcome.</p>
<fig id="pone-0068768-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0068768.g001</object-id><label>Figure 1</label><caption>
<title>Plasma midregional pro-adrenomedullin (MR-proADM) levels in patients on admission.</title>
<p>Patients were dichotomized into favourable (mRS 0–2) and unfavourable (mRS 3–6) outcomes at day 90 after stroke. Plots display the median, interquartile range (box), 10<sup>th</sup> and 90<sup>th</sup> percentiles (whiskers). Abbreviation: mRS  =  modified Rankin Scale; MR-proADM  =  midregional pro-adrenomedullin.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0068768.g001" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0068768-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0068768.t001</object-id><label>Table 1</label><caption>
<title>Demographic data and baseline clinical characteristics of patients.</title>
</caption><alternatives><graphic id="pone-0068768-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0068768.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">all patients</td>
<td align="left" rowspan="1" colspan="1">RS 0–2</td>
<td align="left" rowspan="1" colspan="1">mRS 3–6</td>
<td align="left" rowspan="1" colspan="1">p</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">n</td>
<td align="left" rowspan="1" colspan="1">168</td>
<td align="left" rowspan="1" colspan="1">79</td>
<td align="left" rowspan="1" colspan="1">89</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>median age (range)</bold></td>
<td align="left" rowspan="1" colspan="1">74 years (18–97)</td>
<td align="left" rowspan="1" colspan="1">71 years (18–97)</td>
<td align="left" rowspan="1" colspan="1">79 years (60–89)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>male : female</bold></td>
<td align="left" rowspan="1" colspan="1">85 : 83</td>
<td align="left" rowspan="1" colspan="1">43 : 36</td>
<td align="left" rowspan="1" colspan="1">42 : 47</td>
<td align="left" rowspan="1" colspan="1">0.434</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>median NIHSS on admission</bold></td>
<td align="left" rowspan="1" colspan="1">9 (range 4–25)</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">12</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>recanalization therapy</bold></td>
<td align="left" rowspan="1" colspan="1">90 (53.6%)</td>
<td align="left" rowspan="1" colspan="1">46 (58.2%)</td>
<td align="left" rowspan="1" colspan="1">44 (49.4%)</td>
<td align="left" rowspan="1" colspan="1">0.325</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>hypertension</bold></td>
<td align="left" rowspan="1" colspan="1">130 (77.4%)</td>
<td align="left" rowspan="1" colspan="1">59 (74.7%)</td>
<td align="left" rowspan="1" colspan="1">71 (79.8%)</td>
<td align="left" rowspan="1" colspan="1">0.547</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>hypercholesterolemia</bold></td>
<td align="left" rowspan="1" colspan="1">86 (51.2%)</td>
<td align="left" rowspan="1" colspan="1">50 (63.3%)</td>
<td align="left" rowspan="1" colspan="1">36 (40.4%)</td>
<td align="left" rowspan="1" colspan="1">0.005</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>diabetes mellitus</bold></td>
<td align="left" rowspan="1" colspan="1">40 (23.8%)</td>
<td align="left" rowspan="1" colspan="1">19 (24.1%)</td>
<td align="left" rowspan="1" colspan="1">21 (23.6%)</td>
<td align="left" rowspan="1" colspan="1">0.911</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>atrial fibrillation</bold></td>
<td align="left" rowspan="1" colspan="1">68 (40.5%)</td>
<td align="left" rowspan="1" colspan="1">18 (22.8%)</td>
<td align="left" rowspan="1" colspan="1">50 (56.2%)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>coronary heart disease</bold></td>
<td align="left" rowspan="1" colspan="1">30 (17.9%)</td>
<td align="left" rowspan="1" colspan="1">11 (13.9%)</td>
<td align="left" rowspan="1" colspan="1">19 (21.3%)</td>
<td align="left" rowspan="1" colspan="1">0.293</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>angiotensin convertingenzyme inhibitors</bold></td>
<td align="left" rowspan="1" colspan="1">42 (25.0%)</td>
<td align="left" rowspan="1" colspan="1">16 (20.3%)</td>
<td align="left" rowspan="1" colspan="1">26 (29.2%)</td>
<td align="left" rowspan="1" colspan="1">0.246</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>angiotensinreceptor antagonists</bold></td>
<td align="left" rowspan="1" colspan="1">21 (12.5%)</td>
<td align="left" rowspan="1" colspan="1">8 (10.1%)</td>
<td align="left" rowspan="1" colspan="1">13 (14.6%)</td>
<td align="left" rowspan="1" colspan="1">0.520</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>TACS</bold></td>
<td align="left" rowspan="1" colspan="1">33 (19.6%)</td>
<td align="left" rowspan="1" colspan="1">5 (6.3%)</td>
<td align="left" rowspan="1" colspan="1">28 (31.5%)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>PACS</bold></td>
<td align="left" rowspan="1" colspan="1">101 (60.2%)</td>
<td align="left" rowspan="1" colspan="1">55 (69.6%)</td>
<td align="left" rowspan="1" colspan="1">46 (51.7%)</td>
<td align="left" rowspan="1" colspan="1">0.044</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>POCS</bold></td>
<td align="left" rowspan="1" colspan="1">22 (13.1%)</td>
<td align="left" rowspan="1" colspan="1">10 (12.7%)</td>
<td align="left" rowspan="1" colspan="1">12 (13.5%)</td>
<td align="left" rowspan="1" colspan="1">0.943</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>LACS</bold></td>
<td align="left" rowspan="1" colspan="1">12 (7.1%)</td>
<td align="left" rowspan="1" colspan="1">8 (10.1%)</td>
<td align="left" rowspan="1" colspan="1">4 (4.5%)</td>
<td align="left" rowspan="1" colspan="1">0.265</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>supra–aortic atherosclerosis</bold></td>
<td align="left" rowspan="1" colspan="1">57 (33.9%)</td>
<td align="left" rowspan="1" colspan="1">24 (30.4%)</td>
<td align="left" rowspan="1" colspan="1">33 (37.1%)</td>
<td align="left" rowspan="1" colspan="1">0.452</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>cardio-aortic embolism</bold></td>
<td align="left" rowspan="1" colspan="1">73 (43.5%)</td>
<td align="left" rowspan="1" colspan="1">26 (32.9%)</td>
<td align="left" rowspan="1" colspan="1">47 (52.8%)</td>
<td align="left" rowspan="1" colspan="1">0.025</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>small artery occlusion</bold></td>
<td align="left" rowspan="1" colspan="1">12 (7.1%)</td>
<td align="left" rowspan="1" colspan="1">9 (11.4%)</td>
<td align="left" rowspan="1" colspan="1">3 (3.4%)</td>
<td align="left" rowspan="1" colspan="1">0.086</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>uncommon/undetermined causes of stroke</bold></td>
<td align="left" rowspan="1" colspan="1">26 (15.5%)</td>
<td align="left" rowspan="1" colspan="1">17 (21.5%)</td>
<td align="left" rowspan="1" colspan="1">9 (10.1%)</td>
<td align="left" rowspan="1" colspan="1">0.068</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>Patients were dichotomized into favourable (mRS 0–2) and unfavourable (mRS 3–6) outcomes at day 90 after stroke. P-values for median age and median NIHSS on admission were obtained by Mann-Whitney's U-test. Other p-values were obtained by the Chi-square test or Fisher's exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0068768-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0068768.t002</object-id><label>Table 2</label><caption>
<title>Predictive models for an unfavourable functional outcome (modified Rankin Scale 3–6) at day 90 following stroke.</title>
</caption><alternatives><graphic id="pone-0068768-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0068768.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">variables</td>
<td align="left" rowspan="1" colspan="1">OR (95% CI)</td>
<td align="left" rowspan="1" colspan="1">p</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>model 1</bold> <xref ref-type="table-fn" rid="nt103">a</xref></td>
<td align="left" rowspan="1" colspan="1">age</td>
<td align="left" rowspan="1" colspan="1">1.097 (1.057–1.139)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">NIHSS</td>
<td align="left" rowspan="1" colspan="1">1.193 (1.108–1.284)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">recanalization therapy</td>
<td align="left" rowspan="1" colspan="1">0.587 (0.277–1.245)</td>
<td align="left" rowspan="1" colspan="1">0.160</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>model 2</bold> <xref ref-type="table-fn" rid="nt103">a</xref></td>
<td align="left" rowspan="1" colspan="1">age</td>
<td align="left" rowspan="1" colspan="1">1.090 (1.049–1.132)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">NIHSS</td>
<td align="left" rowspan="1" colspan="1">1.187 (1.100–1.280)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">recanalization therapy</td>
<td align="left" rowspan="1" colspan="1">0.732 (0.332–1.615)</td>
<td align="left" rowspan="1" colspan="1">0.439</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">plasma MR-proADM</td>
<td align="left" rowspan="1" colspan="1">4.062 (1.109–14.87)</td>
<td align="left" rowspan="1" colspan="1">0.028</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><label/><p>Abbreviations: NIHSS  =  National Institutes of Health Stroke Scale; OR  =  Odd's ratio; CI  =  confidence interval.</p></fn><fn id="nt103"><label>a</label><p>Areas under receiver operating characteristics (ROC) curves (AUC) 0.803 and 0.819 for models 1 and 2, respectively (p = 0.204); category-free net reclassification improvement (NRI) 0.577 (p&lt;0.001).</p></fn><fn id="nt104"><label/><p>Abbreviations: mRS  =  modified Rankin Scale; NIHSS  =  National Institutes of Health Stroke Scale; TACS  =  total anterior circulation syndrome; PACS  =  partial anterior circulation syndrome; POCS  =  posterior circulation syndrome; LACS – lacunar syndrome.</p></fn></table-wrap-foot></table-wrap>
<p>With plasma MR-proADM levels in the upper three quintiles, 100%, 83.3% and 75.5% of patients had an unfavourable functional outcome, respectively, as compared to 36.4% and 47.4% of patients in the lower two quintiles. When using the SPAN-100 for outcome prediction (<xref ref-type="table" rid="pone-0068768-t003">table 3</xref>), in 36 patients with unfavourable outcome reclassification improved by MR-proADM, and in 8 patients it became worse, with a net gain in reclassification proportion of 0.31 (p&lt;0.001). Eleven individuals with favourable outcome were falsely reclassified by MR-proADM quintiles (p&lt;0.01). Overall NRI was 0.175 (p = 0.04) indicating an improvement in reclassification of patients by adding plasma MR-proADM to their SPAN-100 status.</p>
<table-wrap id="pone-0068768-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0068768.t003</object-id><label>Table 3</label><caption>
<title>Reclassification table for prediction of functional outcome at day 90 following stroke.</title>
</caption><alternatives><graphic id="pone-0068768-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0068768.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td colspan="2" align="left" rowspan="1"/>
<td colspan="3" align="left" rowspan="1">SPAN-100+ MR-proADM, predicted outcome</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1"/>
<td align="left" rowspan="1" colspan="1">mRS 0–2</td>
<td align="left" rowspan="1" colspan="1">mRS 3–6</td>
<td align="left" rowspan="1" colspan="1">total</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>SPAN-100, predicted outcome</bold></td>
<td colspan="4" align="left" rowspan="1"><bold>events (observed outcome mRS 3–6)</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">mRS 0–2</td>
<td align="left" rowspan="1" colspan="1">33</td>
<td align="left" rowspan="1" colspan="1">36</td>
<td align="left" rowspan="1" colspan="1">69</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">mRS 3–6</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">12</td>
<td align="left" rowspan="1" colspan="1">20</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">total</td>
<td align="left" rowspan="1" colspan="1">41</td>
<td align="left" rowspan="1" colspan="1">48</td>
<td align="left" rowspan="1" colspan="1">89</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td colspan="4" align="left" rowspan="1"><bold>non-events (observed outcome mRS 0–2)</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">mRS 0–2</td>
<td align="left" rowspan="1" colspan="1">66</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">77</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">mRS 3–6</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">total</td>
<td align="left" rowspan="1" colspan="1">66</td>
<td align="left" rowspan="1" colspan="1">13</td>
<td align="left" rowspan="1" colspan="1">79</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt105"><label/><p>Reclassification was performed using the SPAN-100 alone or in combination with MR-proADM quintiles.</p></fn><fn id="nt106"><label/><p>Abbreviations: SPAN  =  Stroke Prognostication using Age and NIHSS; MR-proADM  =  midregional pro-adrenomedullin; mRS  =  modified Rankin Scale.</p></fn></table-wrap-foot></table-wrap>
<p>Patients who died within 90 days following stroke (n = 30) had a higher median NIHSS (15 vs. 7; p&lt;0.001) and higher MR-proADM levels (median 0.92 nmol/l vs. 0.73 nmol/l; p&lt;0.001). The difference in age compared to patients who survived did not reach statistical significance (median 79.0 vs. 73.0 years; p = 0.058). In models to predict the patients' death within 90 days following stroke, the AUC of generated ROC curves did not increase significantly when plasma MR-proADM levels were added to the patients' age, NIHSS and the use of recanalisation therapy (data not shown). Category-free NRI of 0.127 (p = 0.523) showed no improvement in reclassification of patients by adding MR-proADM levels to predict patients' death. Kaplan-Meier survival analysis showed a rising risk of death with increasing MR-proADM quintiles (p = 0.011; <xref ref-type="fig" rid="pone-0068768-g002">figure 2</xref>).</p>
<fig id="pone-0068768-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0068768.g002</object-id><label>Figure 2</label><caption>
<title>Kaplan-Meier survival curves.</title>
<p>Time to death related to plasma MR-proADM quintiles (1<sup>st</sup>: 0.04–0.45 nmol/l; 2<sup>nd</sup>: 0.46–0.86 nmol/l; 3<sup>rd</sup>: 0.87–1.27 nmol/l; 4<sup>th</sup>: 1.28–1.68 nmol/l; 5<sup>th</sup>: 1.69–2.10 nmol/l).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0068768.g002" position="float" xlink:type="simple"/></fig></sec><sec id="s4">
<title>Discussion</title>
<p>Plasma MR-proADM improves prediction of functional outcome in ischemic stroke when added to the patients' age, NIHSS on admission, and the use of recanalization therapy. Levels of MR-proADM in peripheral blood improve reclassification of patients when the SPAN-100 is used in the prediction of functional outcome. Currently, there are no commonly accepted models to predict functional outcome in ischemic stroke. The SPAN-100 has a great advantage in its ease of use in clinical routine and emergency settings. <xref ref-type="bibr" rid="pone.0068768-Rabinstein1">[29]</xref> The mRS at three months is the most prevalent outcome assessment and the preferred outcome measure for treatment trials in acute stroke. <xref ref-type="bibr" rid="pone.0068768-Quinn1">[30]</xref>, <xref ref-type="bibr" rid="pone.0068768-Lees1">[31]</xref> As opposed to other stroke biomarker studies, <xref ref-type="bibr" rid="pone.0068768-DeMarchis1">[4]</xref>–<xref ref-type="bibr" rid="pone.0068768-Katan2">[6]</xref>, <xref ref-type="bibr" rid="pone.0068768-Worthmann1">[32]</xref>, <xref ref-type="bibr" rid="pone.0068768-Worthmann2">[33]</xref> we have excluded patients with minor stroke or transitory ischemic attack which results in a higher median NIHSS in our study. This contributes to the higher percentage of patients in this study who underwent recanalization therapy as compared to average rates in Austrian stroke units in recent years. <xref ref-type="bibr" rid="pone.0068768-Ferrari1">[34]</xref> We could not approach all eligible patients in the given timeframe for participation in the study. However, we included patients consecutively according to the aforementioned criteria irrespective of any clinical prediction of their prognosis and did not include patients with preexisting disability.</p>
<p>Adrenomedullin has been identified as a tumor survival factor <xref ref-type="bibr" rid="pone.0068768-Cuttitta1">[35]</xref> and exerts antimicrobial properties. <xref ref-type="bibr" rid="pone.0068768-Wiesner1">[36]</xref> We have excluded patients with a known malignancy or with signs of infection. In patients with myocardial infarction or CHF, plasma MR-proADM is an independent predictor of death. <xref ref-type="bibr" rid="pone.0068768-Khan1">[8]</xref>, <xref ref-type="bibr" rid="pone.0068768-vonHaehling1">[9]</xref> In our study, Kaplan-Meier survival analysis showed a rising risk of death with increasing plasma level quintiles. MR-proADM levels have previously shown to increase with higher NYHA classes. <xref ref-type="bibr" rid="pone.0068768-vonHaehling1">[9]</xref> In that study, MR-proADM appeared to decrease with the intake of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor antagonists. <xref ref-type="bibr" rid="pone.0068768-vonHaehling1">[9]</xref> In our cohort, we have excluded patients with NYHA classes III and IV. The proportions of patients who were on ACE inhibitor or angiotensin receptor antagonist therapy in our study did not differ in patients with favourable (mRS 0–2) and unfavourable (mRS 3–6) outcomes (<xref ref-type="table" rid="pone-0068768-t001">table 1</xref>). Patients who took either an ACE inhibitor or an angiotensin receptor antagonist on admission had a higher median mRS at day 90 (4 vs. 2; p = 0.015) and higher median MR-proADM levels (0.82 vs. 0.70 nmol/l; p&lt;0.001).</p>
<p>Adrenomedullin is supposed to counter vasoconstricting and sodium-retaining hormones in patients with CHF. <xref ref-type="bibr" rid="pone.0068768-Nicholls1">[37]</xref> The counter-regulation of vasoconstriction as part of a systemic stress response may also apply to patients with acute ischemic stroke. Data from animal models hint to a role of adrenomedullin in neuroprotection, <xref ref-type="bibr" rid="pone.0068768-Maki1">[38]</xref>–<xref ref-type="bibr" rid="pone.0068768-Serrano1">[40]</xref> an issue to be addressed in future clinical trials. The findings from our exploratory study show that the determination of MR-proADM levels in peripheral blood improves prediction of functional outcome in ischemic stroke patients. This should be reassessed in a larger trial to evaluate its applicability in routine clinical procedures.</p>
</sec></body>
<back>
<ack>
<p>The excellent technical assistance of Lusik Balayan and Christina Haas is gratefully acknowledged.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0068768-Weimar1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weimar</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Konig</surname><given-names>IR</given-names></name>, <name name-style="western"><surname>Kraywinkel</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ziegler</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Diener</surname><given-names>HC</given-names></name> (<year>2004</year>) <article-title>Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models</article-title>. <source>Stroke</source> <volume>35</volume>: <fpage>158</fpage>–<lpage>162</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Frendl1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Frendl</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Csiba</surname><given-names>L</given-names></name> (<year>2011</year>) <article-title>Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke</article-title>. <source>Front Neurol</source> <volume>2</volume>: <fpage>32</fpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Whiteley1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Whiteley</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chong</surname><given-names>WL</given-names></name>, <name name-style="western"><surname>Sengupta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sandercock</surname><given-names>P</given-names></name> (<year>2009</year>) <article-title>Blood markers for the prognosis of ischemic stroke: a systematic review</article-title>. <source>Stroke</source> <volume>40</volume>: <fpage>e380</fpage>–<lpage>389</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-DeMarchis1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Marchis</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Katan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Weck</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fluri</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Foerch</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Copeptin adds prognostic information after ischemic stroke: Results from the CoRisk study</article-title>. <source>Neurology</source> <volume>80</volume>: <fpage>1278</fpage>–<lpage>1286</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Katan1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Katan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fluri</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Morgenthaler</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Schuetz</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zweifel</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Copeptin: a novel, independent prognostic marker in patients with ischemic stroke</article-title>. <source>Ann Neurol</source> <volume>66</volume>: <fpage>799</fpage>–<lpage>808</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Katan2"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Katan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fluri</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Schuetz</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Morgenthaler</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Zweifel</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke</article-title>. <source>J Am Coll Cardiol</source> <volume>56</volume>: <fpage>1045</fpage>–<lpage>1053</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Doehner1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Doehner</surname><given-names>W</given-names></name>, <name name-style="western"><surname>von Haehling</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Suhr</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ebner</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Schuster</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke</article-title>. <source>J Am Coll Cardiol</source> <volume>60</volume>: <fpage>346</fpage>–<lpage>354</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Khan1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Khan</surname><given-names>SQ</given-names></name>, <name name-style="western"><surname>O'Brien</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Struck</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Quinn</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Morgenthaler</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study</article-title>. <source>J Am Coll Cardiol</source> <volume>49</volume>: <fpage>1525</fpage>–<lpage>1532</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-vonHaehling1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>von Haehling</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Filippatos</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Papassotiriou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cicoira</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jankowska</surname><given-names>EA</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure</article-title>. <source>Eur J Heart Fail</source> <volume>12</volume>: <fpage>484</fpage>–<lpage>491</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Gumusel1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gumusel</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Hyman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lippton</surname><given-names>H</given-names></name> (<year>1995</year>) <article-title>Adrenotensin: an ADM gene product with the opposite effects of ADM</article-title>. <source>Life Sci</source> <volume>57</volume>: <fpage>PL87</fpage>–<lpage>90</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Sugo1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sugo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Minamino</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Shoji</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kangawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kitamura</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>1994</year>) <article-title>Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha</article-title>. <source>Biochem Biophys Res Commun</source> <volume>203</volume>: <fpage>719</fpage>–<lpage>726</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Sugo2"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sugo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Minamino</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kangawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Miyamoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kitamura</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>1994</year>) <article-title>Endothelial cells actively synthesize and secrete adrenomedullin</article-title>. <source>Biochem Biophys Res Commun</source> <volume>201</volume>: <fpage>1160</fpage>–<lpage>1166</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Kitamura1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kitamura</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kangawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kawamoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ichiki</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Nakamura</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>1993</year>) <article-title>Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma</article-title>. <source>Biochem Biophys Res Commun</source> <volume>192</volume>: <fpage>553</fpage>–<lpage>560</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Kato1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tsuruda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kita</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kitamura</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Eto</surname><given-names>T</given-names></name> (<year>2005</year>) <article-title>Adrenomedullin: a protective factor for blood vessels</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>25</volume>: <fpage>2480</fpage>–<lpage>2487</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Pio1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pio</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Martinez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Unsworth</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Kowalak</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Bengoechea</surname><given-names>JA</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners</article-title>. <source>J Biol Chem</source> <volume>276</volume>: <fpage>12292</fpage>–<lpage>12300</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Meeran1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meeran</surname><given-names>K</given-names></name>, <name name-style="western"><surname>O'Shea</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Upton</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Small</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Ghatei</surname><given-names>MA</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study</article-title>. <source>J Clin Endocrinol Metab</source> <volume>82</volume>: <fpage>95</fpage>–<lpage>100</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Struck1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Struck</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Morgenthaler</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Bergmann</surname><given-names>A</given-names></name> (<year>2004</year>) <article-title>Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients</article-title>. <source>Peptides</source> <volume>25</volume>: <fpage>1369</fpage>–<lpage>1372</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Morgenthaler1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morgenthaler</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Struck</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Alonso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bergmann</surname><given-names>A</given-names></name> (<year>2005</year>) <article-title>Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay</article-title>. <source>Clin Chem</source> <volume>51</volume>: <fpage>1823</fpage>–<lpage>1829</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Brott1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brott</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>HP</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Olinger</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Marler</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Barsan</surname><given-names>WG</given-names></name>, <etal>et al</etal>. (<year>1989</year>) <article-title>Measurements of acute cerebral infarction: a clinical examination scale</article-title>. <source>Stroke</source> <volume>20</volume>: <fpage>864</fpage>–<lpage>870</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-vanSwieten1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Swieten</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Koudstaal</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Visser</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Schouten</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>van Gijn</surname><given-names>J</given-names></name> (<year>1988</year>) <article-title>Interobserver agreement for the assessment of handicap in stroke patients</article-title>. <source>Stroke</source> <volume>19</volume>: <fpage>604</fpage>–<lpage>607</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Janssen1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Janssen</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Visser</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Dorhout Mees</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Klijn</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Algra</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Comparison of telephone and face-to-face assessment of the modified Rankin Scale</article-title>. <source>Cerebrovasc Dis</source> <volume>29</volume>: <fpage>137</fpage>–<lpage>139</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Saposnik1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saposnik</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Guzik</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Reeves</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ovbiagele</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>SC</given-names></name> (<year>2013</year>) <article-title>Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100</article-title>. <source>Neurology</source> <volume>80</volume>: <fpage>21</fpage>–<lpage>28</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Bamford1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bamford</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sandercock</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dennis</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Burn</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Warlow</surname><given-names>C</given-names></name> (<year>1991</year>) <article-title>Classification and natural history of clinically identifiable subtypes of cerebral infarction</article-title>. <source>Lancet</source> <volume>337</volume>: <fpage>1521</fpage>–<lpage>1526</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Ay1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ay</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Benner</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Arsava</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Furie</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Singhal</surname><given-names>AB</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System</article-title>. <source>Stroke</source> <volume>38</volume>: <fpage>2979</fpage>–<lpage>2984</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-DeLong1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DeLong</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>DeLong</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Clarke-Pearson</surname><given-names>DL</given-names></name> (<year>1988</year>) <article-title>Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach</article-title>. <source>Biometrics</source> <volume>44</volume>: <fpage>837</fpage>–<lpage>845</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Pencina1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pencina</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>D'Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name>, <name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></name> (<year>2011</year>) <article-title>Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers</article-title>. <source>Stat Med</source> <volume>30</volume>: <fpage>11</fpage>–<lpage>21</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Pencina2"><label>27</label>
<mixed-citation publication-type="other" xlink:type="simple">Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157–172; discussion 207–112.</mixed-citation>
</ref>
<ref id="pone.0068768-Faul1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faul</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Erdfelder</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Buchner</surname><given-names>A</given-names></name> (<year>2007</year>) <article-title>G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title>. <source>Behav Res Methods</source> <volume>39</volume>: <fpage>175</fpage>–<lpage>191</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Rabinstein1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rabinstein</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rundek</surname><given-names>T</given-names></name> (<year>2013</year>) <article-title>Prediction of outcome after ischemic stroke: The value of clinical scores</article-title>. <source>Neurology</source> <volume>80</volume>: <fpage>15</fpage>–<lpage>16</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Quinn1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Quinn</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Dawson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Walters</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Lees</surname><given-names>KR</given-names></name> (<year>2009</year>) <article-title>Functional outcome measures in contemporary stroke trials</article-title>. <source>Int J Stroke</source> <volume>4</volume>: <fpage>200</fpage>–<lpage>205</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Lees1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lees</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Bath</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Schellinger</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Kerr</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Fulton</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Contemporary outcome measures in acute stroke research: choice of primary outcome measure</article-title>. <source>Stroke</source> <volume>43</volume>: <fpage>1163</fpage>–<lpage>1170</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Worthmann1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Worthmann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tryc</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Goldbecker</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>YT</given-names></name>, <name name-style="western"><surname>Tountopoulou</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome</article-title>. <source>Cerebrovasc Dis</source> <volume>30</volume>: <fpage>85</fpage>–<lpage>92</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Worthmann2"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Worthmann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kempf</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Widera</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tryc</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Goldbecker</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Growth differentiation factor 15 plasma levels and outcome after ischemic stroke</article-title>. <source>Cerebrovasc Dis</source> <volume>32</volume>: <fpage>72</fpage>–<lpage>78</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Ferrari1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ferrari</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Knoflach</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kiechl</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Willeit</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Matosevic</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Stroke thrombolysis: having more time translates into delayed therapy: data from the Austrian Stroke Unit Registry</article-title>. <source>Stroke</source> <volume>41</volume>: <fpage>2001</fpage>–<lpage>2004</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Cuttitta1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cuttitta</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Pio</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Garayoa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zudaire</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Julian</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Adrenomedullin functions as an important tumor survival factor in human carcinogenesis</article-title>. <source>Microsc Res Tech</source> <volume>57</volume>: <fpage>110</fpage>–<lpage>119</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Wiesner1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wiesner</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vilcinskas</surname><given-names>A</given-names></name> (<year>2010</year>) <article-title>Antimicrobial peptides: the ancient arm of the human immune system</article-title>. <source>Virulence</source> <volume>1</volume>: <fpage>440</fpage>–<lpage>464</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Nicholls1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nicholls</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Charles</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Lainchbury</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>LK</given-names></name>, <name name-style="western"><surname>Rademaker</surname><given-names>MT</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Adrenomedullin in heart failure</article-title>. <source>Hypertens Res</source> <volume>26</volume> Suppl: S135–140</mixed-citation>
</ref>
<ref id="pone.0068768-Maki1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ihara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fujita</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Nambu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Miyashita</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Angiogenic and vasoprotective effects of adrenomedullin on prevention of cognitive decline after chronic cerebral hypoperfusion in mice</article-title>. <source>Stroke</source> <volume>42</volume>: <fpage>1122</fpage>–<lpage>1128</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Encinas1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Encinas</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Serrano</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Alonso</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fernandez</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Rodrigo</surname><given-names>J</given-names></name> (<year>2002</year>) <article-title>Adrenomedullin over-expression in the caudate-putamen of the adult rat brain after ischaemia-reperfusion injury</article-title>. <source>Neurosci Lett</source> <volume>329</volume>: <fpage>197</fpage>–<lpage>200</lpage>.</mixed-citation>
</ref>
<ref id="pone.0068768-Serrano1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Serrano</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Alonso</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Encinas</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Lopez</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Fernandez</surname><given-names>AP</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Adrenomedullin expression is up-regulated by ischemia-reperfusion in the cerebral cortex of the adult rat</article-title>. <source>Neuroscience</source> <volume>109</volume>: <fpage>717</fpage>–<lpage>731</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>